Tapentadol Depot STADA 25 mg

What Is Tapentadol Depot STADA and What Is It Used For?

Tapentadol Depot STADA contains the active substance tapentadol (as tapentadol hydrochloride). Tapentadol is a member of the opioid analgesic class, but it is pharmacologically distinct from traditional strong opioids such as morphine, oxycodone, or fentanyl. Its defining feature is a dual mechanism of action often abbreviated as MOR-NRI: mu-opioid receptor agonism combined with norepinephrine reuptake inhibition. This means that tapentadol acts simultaneously on two independent but complementary pain-modulating pathways in the central nervous system — a property that may be particularly advantageous in chronic pain conditions that have both nociceptive (tissue-damage) and neuropathic (nerve-related) components.

The first mechanism — mu-opioid receptor agonism — is the classical opioid effect. By binding to and activating mu-opioid receptors in the brain and spinal cord, tapentadol dampens the transmission and perception of pain signals. The second mechanism — norepinephrine reuptake inhibition — enhances the activity of descending inhibitory pain pathways that originate in the brainstem and project down to the spinal cord. These descending pathways use norepinephrine (noradrenaline) as a neurotransmitter to suppress incoming pain signals. By preventing the reuptake of norepinephrine, tapentadol strengthens this endogenous pain-control system. Clinical evidence suggests this dual action can provide analgesic efficacy comparable to pure mu-opioid agonists at equianalgesic doses, with a somewhat more favorable gastrointestinal tolerability profile, and with particular benefit for pain that involves a neuropathic component (such as painful diabetic peripheral neuropathy or chronic low back pain with radicular features).

The distinguishing feature of Tapentadol Depot STADA compared with immediate-release tapentadol is its prolonged-release (depot) formulation. The active ingredient is embedded in a hydrophilic matrix that releases tapentadol slowly as it passes through the gastrointestinal tract. Measurable plasma concentrations appear within about one hour of swallowing the tablet, peak concentrations are reached between 3 and 6 hours, and therapeutic levels are maintained for approximately 12 hours. This pharmacokinetic profile supports twice-daily dosing and produces stable plasma concentrations, avoiding the peaks and troughs seen with short-acting formulations. For patients with chronic pain that requires continuous analgesia, a depot formulation reduces the number of daily doses, improves adherence, and is thought to decrease the reward-associated peak concentrations that drive opioid misuse.

Typical clinical indications for which prolonged-release tapentadol may be prescribed include:

• Severe chronic non-cancer pain: such as chronic low back pain with or without a radicular component, severe osteoarthritis pain unresponsive to non-opioid therapy, and chronic post-surgical pain syndromes.
• Chronic neuropathic pain: including painful diabetic peripheral neuropathy, post-herpetic neuralgia, and other neuropathic pain states where tapentadol's noradrenergic activity may add benefit.
• Mixed pain syndromes: chronic pain conditions that contain both nociceptive (musculoskeletal, inflammatory) and neuropathic elements.
• Chronic cancer pain in selected patients, as part of a WHO analgesic-ladder strategy and under close specialist supervision.

The 25 mg strength is the lowest prolonged-release strength of tapentadol available. It is used primarily for treatment initiation in opioid-naive patients, for dose titration, and for fine adjustment of the total daily dose when a patient is between higher-strength tablets. In clinical practice, patients typically start at 25 or 50 mg twice daily and the dose is adjusted upward every few days based on pain relief and tolerability.

It is important to understand that tapentadol is reserved for chronic pain that is genuinely severe and that has not responded sufficiently to non-opioid analgesics or to weaker opioid strategies. It should not be used for mild pain, for acute pain that is expected to resolve within days, or as a first-line analgesic. In line with modern opioid-stewardship principles — endorsed by the CDC, NICE, and many national bodies — long-term opioid therapy should be prescribed at the lowest effective dose for the shortest clinically necessary duration, with regular review of benefit, harm, and function. The prescribing physician will have judged that the benefits of opioid therapy outweigh the known risks in your individual clinical situation.

Tapentadol Depot STADA is manufactured and distributed by STADA Arzneimittel AG, a German-headquartered international pharmaceutical company that specializes in generic and specialty medicines. It is available as 25 mg prolonged-release tablets intended for oral administration.

What Should You Know Before Taking Tapentadol Depot STADA?

Before starting Tapentadol Depot STADA, your doctor will review your full medical history, current medications, and any risk factors for opioid-related complications. Provide honest and complete information about any previous or current use of alcohol, prescription medications, and illicit substances, as well as any mental-health conditions. This information is essential for safe prescribing and does not result in judgment — it allows your doctor to tailor therapy appropriately and minimize the risk of serious adverse events.

Because this is a prolonged-release (depot) formulation, specific practical points require particular attention before and during therapy: the tablets must always be swallowed whole; the dose cannot be "split"; and once steady-state has been established after a few days of regular dosing, changes in dose or timing should only be made under medical direction.

Contraindications

You must not take Tapentadol Depot STADA if any of the following apply to you:

• Hypersensitivity to tapentadol or to any of the excipients listed in the product information.
• Conditions where mu-opioid receptor agonists are contraindicated: including significant respiratory depression and acute or severe bronchial asthma or hypercapnia in unmonitored settings or in the absence of resuscitative equipment.
• Known or suspected paralytic ileus. Opioids further slow bowel motility and can precipitate life-threatening complications. Tapentadol depot tablets also rely on an intact and functioning gastrointestinal tract for their prolonged-release performance.
• Acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic medicines (drugs affecting mood, mental function, or behavior). The combined central nervous system (CNS)-depressant effect can be lethal.
• Concurrent use of monoamine oxidase (MAO) inhibitors or use within the last 14 days. This combination can precipitate serotonin syndrome, severe hypertensive crisis, and cardiovascular collapse.
• Severe hepatic impairment (Child-Pugh class C). Tapentadol is extensively metabolized in the liver and is contraindicated in patients with severe hepatic impairment.
• Severe renal impairment. The safety and efficacy of tapentadol have not been established in patients with severe renal impairment, and the product is not recommended in this group.
• Conditions where opioids are contraindicated, including patients with severe central respiratory depression, suspected surgical abdomen, and moderate to severe hepatic impairment in some regulatory regions.
• Paediatric use. Tapentadol Depot STADA is not indicated and not recommended in children and adolescents under 18 years of age.

Warnings and Precautions

Talk to your doctor or pharmacist before taking Tapentadol Depot STADA if any of the following apply:

• Respiratory conditions: Slow or shallow breathing, chronic obstructive pulmonary disease (COPD), cor pulmonale, sleep apnea, obesity-hypoventilation syndrome, or any condition that compromises respiratory reserve. Tapentadol can cause life-threatening respiratory depression, especially in elderly or debilitated patients, at initiation of therapy, after dose increases, and when combined with other CNS depressants.
• Head injury or raised intracranial pressure: Tapentadol may obscure the clinical picture in patients with head injuries and can contribute to increases in intracranial pressure. Use with caution and close clinical monitoring.
• Hepatic impairment: Patients with moderate hepatic impairment (Child-Pugh class B) require careful dose titration and extended dosing intervals. Severe hepatic impairment is a contraindication.
• Renal impairment: No dose adjustment is generally required for mild or moderate renal impairment, but caution is advised. Severe renal impairment is a contraindication.
• Biliary or pancreatic disease: Opioids, including tapentadol, can cause spasm of the sphincter of Oddi and may worsen pancreatitis or biliary obstruction.
• Seizure disorders or epilepsy: Tapentadol may lower the seizure threshold, particularly when combined with other medications that also lower the threshold (some antidepressants, antipsychotics, bupropion, certain antibiotics).
• Mental-health conditions: Depression, anxiety, post-traumatic stress disorder, and personality disorders may complicate opioid therapy and increase the risk of misuse. Discuss your psychiatric history openly with your prescriber.
• History of substance use disorder: Personal or family history of alcohol, prescription, or illicit drug misuse is a significant risk factor for opioid addiction. This does not necessarily preclude treatment but warrants closer monitoring and, in many cases, specialist pain-medicine input.
• Elderly patients: Older adults are more sensitive to opioid side effects, particularly sedation, confusion, orthostatic hypotension, falls, and respiratory depression. Lower starting doses and slower titration may be appropriate.
• Gastrointestinal motility conditions: Because depot tablets rely on passage through the gastrointestinal tract at a normal rate, conditions that markedly accelerate transit (severe diarrhea) or delay emptying can alter absorption.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Tapentadol Depot STADA.

• Pregnancy: Tapentadol should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus and no safer alternative is available. Prolonged use during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS), which can be life-threatening to the newborn if not recognized and treated promptly. Symptoms in the newborn include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremor, vomiting, diarrhea, and failure to gain weight.
• Labor and delivery: Tapentadol is not recommended during childbirth. It may cause respiratory depression in the newborn.
• Breastfeeding: Tapentadol and its metabolites may pass into human breast milk. Because of the potential for serious adverse reactions in nursing infants, including respiratory depression, breastfeeding is not recommended during treatment with tapentadol.
• Fertility: Chronic opioid therapy can cause endocrine disturbances affecting sex hormones (hypogonadism) and may reduce fertility in both men and women. This usually reverses on discontinuation.

Driving and Operating Machinery

Tapentadol can significantly impair reaction time, cognitive processing, and motor coordination through its effects on the central nervous system. Common effects include drowsiness, dizziness, blurred vision, and impaired attention. These effects are most pronounced at the start of treatment, following dose increases, with changes in formulation, and when combined with alcohol or sedative medications. Do not drive, operate heavy machinery, or perform any activities requiring full alertness until you know how tapentadol affects you. Many patients on stable long-term therapy are able to drive safely, but this must be established individually and in consultation with the prescriber. In many jurisdictions, driving under the influence of prescribed opioids may still constitute a legal offense if driving ability is impaired.

How Does Tapentadol Depot STADA Interact with Other Drugs?

Drug interactions with tapentadol can be dangerous and sometimes fatal. The dual mechanism of action (mu-opioid agonism and norepinephrine reuptake inhibition) creates interaction potential with a broader range of medications than traditional pure-opioid analgesics. Review your complete medication list with your prescriber before starting treatment, including prescription drugs, over-the-counter preparations, vitamins, and herbal supplements such as St. John's Wort. Because Tapentadol Depot STADA is used for chronic pain, interactions with long-term medications (for example, antidepressants, anticonvulsants, sleep aids, or antihypertensives) are a particularly important consideration.

Major Interactions (Potentially Life-Threatening)

Moderate Interactions

Always inform your healthcare team about every medication you are taking, including prescription drugs, over-the-counter medicines (such as cold remedies that may contain sedating antihistamines or dextromethorphan), vitamins, minerals, and herbal supplements. Some seemingly innocuous over-the-counter or natural products can have serious interactions with tapentadol.

What Is the Correct Dosage of Tapentadol Depot STADA?

Tapentadol Depot STADA should always be taken exactly as prescribed. The prescribing physician will individualize your dose based on pain severity, prior analgesic experience (opioid-naive vs. opioid-experienced), age, coexisting medical conditions, and concurrent medications. The guiding principle in modern opioid prescribing is to use the lowest effective dose for the shortest clinically necessary duration, with regular review of benefit and harm.

Adults

Children and Adolescents

Elderly Patients

Patients with Organ Impairment

How to Take the Tablets

Tapentadol Depot STADA is taken orally (by mouth). The following instructions are critical for safe and effective use:

• Swallow the tablet whole with sufficient water or other liquid. Do not crush, chew, break, split, or dissolve the tablet. Doing so will destroy the prolonged-release matrix and can cause a fatal overdose.
• The tablets can be taken with or without food — food does not meaningfully affect absorption.
• Take the doses approximately 12 hours apart — for example, at 8 a.m. and 8 p.m. — to maintain stable plasma levels.
• If you cannot swallow the tablet whole, speak with your doctor about alternative formulations. Never attempt to disguise the dose by breaking or crushing.
• Use a pain diary if helpful, recording pain intensity, time and dose of medication, side effects, and activity level. This helps your doctor fine-tune therapy.

Missed Dose

If you miss a dose of Tapentadol Depot STADA, take the missed dose as soon as you remember, unless it is within about 4 hours of your next scheduled dose. In that case, skip the missed dose and continue with your next regularly scheduled dose. Do not take a double dose to make up for a missed one. Doubling the dose can cause severe respiratory depression and overdose. If you have missed several doses or have had an interruption in therapy, contact your doctor for advice on whether re-titration is needed; opioid tolerance can decrease significantly within a few days.

Overdose

If you (or someone else) have taken too much Tapentadol Depot STADA, or if a child has accidentally ingested the medication, seek emergency medical help immediately. Call your local emergency number or poison control center without delay. Because the depot formulation releases tapentadol over approximately 12 hours, the effects of an overdose may be prolonged and require extended observation and treatment even after symptoms initially improve.

Symptoms of opioid overdose may include:

• Pinpoint pupils (miosis)
• Extreme drowsiness progressing to unconsciousness
• Cold, clammy, or bluish skin (cyanosis)
• Slow, shallow, or absent breathing (respiratory depression or arrest)
• Vomiting — with risk of aspiration in an unconscious patient
• Slow heart rate (bradycardia) and low blood pressure (hypotension)
• Seizures
• Collapse and coma

Respiratory depression is the leading cause of death in opioid overdose. The opioid antagonist naloxone can reverse respiratory depression caused by tapentadol; however, because the duration of action of naloxone is often shorter than that of a depot opioid, repeat naloxone doses or a continuous infusion are frequently required, and admission for monitoring is essential. Patients at higher risk of overdose, or those living with them, may be prescribed take-home naloxone as a safety precaution, particularly those on high doses or those with concurrent CNS-depressant therapy.

Stopping Treatment

Do not stop Tapentadol Depot STADA abruptly after prolonged use. Sudden discontinuation can precipitate opioid withdrawal, which, although not usually life-threatening in otherwise healthy adults, is distressing and includes:

• Restlessness, anxiety, irritability, and insomnia
• Yawning, watering eyes, runny nose, sneezing, sweating, and chills
• Muscle aches, joint pain, back pain, and tremors
• Abdominal cramps, nausea, vomiting, and diarrhea
• Dilated pupils, increased heart rate, and increased blood pressure

Your doctor will construct a gradual dose-reduction (tapering) schedule tailored to your total daily dose and duration of use. A typical approach reduces the daily dose by 10–25% every 1 to 4 weeks; faster tapers may be used in short-term therapy, and slower tapers may be appropriate after long-term high-dose use. Tapering plans should be individualized and supported, and addressing pain and non-pain symptoms during the taper is important. If tapering becomes difficult, specialist pain-medicine or addiction-medicine input is often helpful.

What Are the Side Effects of Tapentadol Depot STADA?

Like all medicines, Tapentadol Depot STADA can cause side effects, although not every person experiences them. The profile reflects its opioid mechanism together with noradrenergic effects. Many common adverse effects — particularly nausea and drowsiness — often diminish within the first one to two weeks as tolerance develops. Constipation, however, typically does not resolve and may need preventive treatment with a stool softener or stimulant laxative from the start of therapy. Opioid-induced bowel dysfunction is a clinically important long-term concern in chronic opioid therapy and should be actively managed rather than accepted.

If you experience any side effects, including those not listed above, discuss them with your doctor or pharmacist. Post-marketing surveillance (adverse-event reporting) is important for continued monitoring of the benefit-risk balance of all medicines. You can report suspected adverse reactions through your national pharmacovigilance authority (for example, the MHRA Yellow Card scheme in the UK, the FDA MedWatch program in the United States, or EudraVigilance in the European Union).

How Should You Store Tapentadol Depot STADA?

Proper storage of opioid medications is critically important for safety, particularly in households with children, adolescents, or individuals at risk of substance misuse. Tapentadol is a controlled substance and is a target for diversion; secure storage protects both household members and the wider community.

• Keep out of the sight and reach of children. A single accidental depot tablet can cause fatal respiratory depression in a child, and the slow release of a prolonged-release product can delay or prolong overdose effects, making pediatric ingestion particularly dangerous.
• Consider storing the medication in a locked cabinet or lockbox, especially in households where visitors or family members may have a history of substance misuse.
• Store at room temperature (below 25°C / 77°F). No special refrigeration is required. Keep in the original container to protect against moisture and light.
• Do not use the medicine after the expiry date printed on the packaging (after "EXP"). The expiry date refers to the last day of that month.
• Do not use the medicine if the tablets appear damaged, discolored, or if the packaging seal has been compromised.
• Disposal: Do not flush unused tablets down the toilet or throw them in household waste. Return unused medication to your pharmacy for safe disposal through an approved take-back program. This protects the environment and prevents accidental exposure or diversion.

If you have leftover medication after your pain has resolved or after a dose change, dispose of it promptly. Keeping unused opioids in the home is one of the leading contributors to accidental ingestion in children, adolescent experimentation with prescription drugs, and diversion for non-medical use. Many pharmacies, hospitals, and local authorities operate take-back programs precisely for this purpose.

What Does Tapentadol Depot STADA Contain?

Active Ingredient

Each Tapentadol Depot STADA prolonged-release tablet contains tapentadol hydrochloride equivalent to 25 mg of tapentadol as the base. Tapentadol is a white to slightly off-white crystalline powder that is freely soluble in water.

Inactive Ingredients (Excipients)

The typical inactive ingredients in prolonged-release tapentadol tablets include:

Tablet core: hypromellose (as part of the hydrophilic release-controlling matrix), microcrystalline cellulose, colloidal anhydrous silicon dioxide (colloidal silica), magnesium stearate, and other standard matrix and compression excipients that together control the release profile.

Film coating: polyvinyl alcohol (or similar polymer), titanium dioxide (E171), macrogol (polyethylene glycol), talc, and pharmaceutical-grade iron oxide pigments for color coding of the strength.

Tablet Appearance and Pack Sizes

Tapentadol Depot STADA 25 mg prolonged-release tablets are typically supplied as small, film-coated, colored tablets; the exact color coding for the 25 mg strength varies between regions and generic manufacturers. The tablet may bear a company or product identifier imprint. Specific visual appearance, dimensions, and pack sizes may vary by country and batch — always cross-check with the dispensed product information. Typical pack sizes include blister packs of 10, 20, 30, 50, 60, or 100 tablets.